Mineralcorticoid antagonists in heart failure

Emilia D'Elia, Henry Krum

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


Mineralocorticoid receptor antagonists (MRAs) have become mandated therapy in patients with reduced ejection fraction (systolic) heart failure (HF) across all symptom classes. These agents should also be prescribed in the early post-myocardial infarction setting in those with reduced ejection fraction and either HF symptoms or diabetes. This article explores the pathophysiological role of aldosterone, an endogenous ligand for the mineralcorticoid receptor (MR), and summarizes the clinical data supporting guideline recommendations for these agents in systolic HF. The use of MRAs in novel areas beyond systolic HF ejection is also explored. Finally, the current status of newer agents will be examined.
Original languageEnglish
Pages (from-to)559 - 564
Number of pages6
JournalHeart Failure Clinics
Issue number4
Publication statusPublished - 2014

Cite this